2021 EADV – New Janssen Data Shows Improvement For PsO Patients Being Treated with TREMFYA (guselkumab)
Dr. Lloyd Miller, MD, PhD, Vice President, Immunodermatology Disease Area Leader at Janssen, discusses new data presented at the 2021 European Academy of Dermatology Venereology Congress (EADV) showing TREMFYA provided durable complete and almost complete skin clearance responses and was well-tolerated with low risk of infection and low rates of anti-drug antibodies in psoriasis (PsO) through up to five years. The patient population studied included PsO patients who switched to TREMFYA from adalimumab. Lloyd talks about what these results mean for patients and healthcare providers.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Surgery. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Surgery and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Surgery?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Lloyd S. Miller, M.D., Ph.D., is Vice President, Immunodermatology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, Lloyd drives the development and implementation of the scientific strategy for immunodermatology to help meet the needs of the millions of patients living with immune-mediated skin diseases.
Prior to Janssen, Lloyd served as Vice Chair for Research in Dermatology within the Department of Dermatology at Johns Hopkins. He was also a Professor of Dermatology, Infectious Diseases, Orthopedic Surgery and Materials Science and Engineering at the Johns Hopkins University School of Medicine.
A known leader in dermatology, Lloyd has published more than 100 peer-reviewed manuscripts, review articles, book chapters and editorials and has given more than 75 oral presentations at national and international scientific programs and meetings. Lloyd has received several grants from the National Institutes of Health (NIH), in addition to private foundation and industry funding for his research.
Lloyd received his M.D. and Ph.D. from the State University of New York Downstate Medical Center in Brooklyn, New York. He completed his dermatology residency and post-doctoral research fellowship in the Specialty Training and Advanced Research program at the University of California, Los Angeles.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
